WHO Panel Set to Decide on Emergency Use of Chinese Vaccine

GENEVA — A key World Health Organization panel was set to decide Friday whether to authorize emergency of a Chinese-made COVID-19 vaccine, a WHO spokesperson said, potentially paving the way for millions of doses to reach needy countries through a U.N.-backed program. 

The review by a technical advisory group could open the possibility of the Sinopharm vaccine being included in the U.N.-backed COVAX program in the coming weeks or months, and distributed through WHO's regional office for the Americas and the U.N. children's agency UNICEF.

WHO spokesman Christian Lindmeier said a decision was expected later Friday. 

Apart from efficacy information, Sinopharm has released very little public data about its two vaccines – one developed by its Beijing Institute of Biological Products and the other by the Wuhan Institute of Biological Products. 

The Beijing shot is one that WHO is considering for an emergency use listing. 

A separate group advising the U.N. agency on vaccines said it was "very confident" the Sinopharm vaccine protects people ages 18-59. The group said it had a "low level of confidence" of vaccine's efficacy in people 60 and over. It expressed "very low confidence" in the available data about potentially serious side effects in that age group. 


MACAO — Only a few tourists crisscrossed the wavy black and white paving of Macao's historic Senado Square on a recent weekday and many of the shops were shuttered.

Top Stories


A pregnant woman was driving in the HOV lane near Dallas.

General News

FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.

General News

NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.


Enter your email address to subscribe

Provide your email address to subscribe. For e.g. [email protected]

You may unsubscribe at any time using the link in our newsletter.